PARP1 and CBP lose their footing in cancer
Crossref DOI link: https://doi.org/10.1038/nsmb.2913
Published Online: 2014-11-05
Published Print: 2014-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Timinszky, Gyula
Ladurner, Andreas G
Text and Data Mining valid from 2014-11-01
Article History
First Online: 5 November 2014
Competing interests
: Andreas Ladurner is on the Scientific Advisory Board of VolitionRx.